The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The U.S. Food and Drug Administration’s (or FDA) approval for Keytruda on October 2, 2015, to treat patients suffering with advanced non-small cell lung cancer (or NSCLC) is considered to be a major ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...

Merck & Co., Inc. MRK announced that the FDA has granted priority review to a supplemental new drug application (sBLA) for its PD-L1 inhibitor, Keytruda. With the latest filing, Merck is looking to ...

CHICAGO, June 1 (Reuters) - Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...

NEW YORK (Reuters) - Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment ...